Epstein-Barr virus (EBV) serves as a principal oncogenic driver in endemic nasopharyngeal carcinoma. While platinum-based chemoradiotherapy remains the established frontline treatment standard, clinicians frequently encounter therapeutic failure and tumor relapse. Emerging molecular insights demonstrate that metabolic reprogramming directly orchestrates cisplatin resistance in NPC, creating substantial barriers to durable disease remission. Understanding the exact molecular circuitry connecting viral oncoproteins to altered cellular metabolism is therefore essential for developing effective targeted interventions and improving patient outcomes in oncology practice.

The Metabolic Reprogramming Landscape and Cisplatin Resistance in NPC

Malignant cells fundamentally reprogram their metabolic machinery to support rapid proliferation and evade cytotoxic insults. In EBV-associated nasopharyngeal carcinoma, viral persistence actively reshapes intracellular metabolic fluxes. Advanced metabolomic and metabolic flux analyses demonstrate that EBV infection selectively enhances polyamine anabolism. Polyamines, including putrescine, spermidine, and spermine, are essential aliphatic cations that regulate nucleic acid stability, protein synthesis, and cellular survival under genotoxic stress.

The rate-limiting step of polyamine biosynthesis depends directly on ornithine decarboxylase 1 (ODC1). In EBV-positive nasopharyngeal carcinoma cells, researchers identified that the immediate-early viral transactivator BZLF1 binds directly to the ODC1 gene promoter. This transcriptional activation causes robust upregulation of ODC1 expression. Consequently, elevated polyamine synthesis fuels both cancer cell survival and EBV lytic cycle replication, forming a resilient feed-forward loop that undermines standard cytotoxic chemotherapy regimens.

Mechanistic Insights: The ODC1-Spermidine Axis and Viral Replication

The downstream consequences of ODC1 activation extend far beyond baseline nutrient processing. Elevated intracellular spermidine levels directly facilitate eukaryotic translation initiation factor 5A (eIF5A) hypusination. Hypusinated eIF5A is a specialized post-translational modification necessary for the efficient translation of mRNAs containing difficult polyproline motifs.

Through this hypusination cascade, the ODC1-spermidine axis selectively upregulates EBV early antigen D (EBV-EAD) alongside host tumor necrosis factor receptor-associated factor 1 (TRAF1). Upregulated EBV-EAD actively accelerates viral genomic replication, whereas host TRAF1 provides potent anti-apoptotic signaling that drives aberrant tumor cell proliferation. Consequently, the pathogen exploits host biosynthetic machinery to sustain both viral propagation and malignant clonal expansion, thereby compounding disease aggressiveness.

Structural DNA Alterations and Immune Evasion

In addition to translational control, high polyamine concentrations induce structural alterations in cellular chromatin. Excess spermidine and spermine stabilize the transition of classical right-handed B-DNA into the alternative left-handed Z-DNA conformation. This B-to-Z DNA conformational transition significantly alters the biophysical accessibility of cytosolic nucleic acids.

Under normal physiological conditions, aberrant cytosolic DNA triggers the cyclic GMP-AMP synthase and stimulator of interferon genes (cGAS-STING) signaling pathway, inducing robust innate antitumor immunity. However, Z-DNA formation effectively attenuates cGAS-STING recognition and dampens downstream type I interferon responses. Cisplatin exerts cytotoxic action partly by inducing DNA leakage into the cytoplasm to stimulate innate immune surveillance. By inducing Z-DNA conformation and attenuating cGAS-STING activation, the ODC1-polyamine axis effectively shields tumor cells from immune clearance, establishing profound cisplatin resistance.

Clinical Prognosis and Pharmacological Reversal with DFMO

Clinical evaluation confirms that high ODC1 expression serves as an independent prognostic biomarker for poor overall and progression-free survival in patients with nasopharyngeal carcinoma. Elevated ODC1 expression strongly correlates with advanced clinical staging, treatment failure, and early distant metastasis. These clinical observations validate ODC1 as a pivotal molecular determinant of treatment response.

Importantly, genetic silencing of ODC1 or pharmacological inhibition using difluoromethylornithine (DFMO) effectively reverses this malignant phenotype. In vitro and in vivo models confirm that DFMO treatment depletes intracellular polyamines, suppresses eIF5A hypusination, and prevents Z-DNA transition. As a result, DFMO treatment reactivates the cGAS-STING pathway and restores cisplatin sensitivity in EBV-positive nasopharyngeal carcinoma cells. Combining polyamine depletion with platinum agents represents an actionable approach to overcome stubborn chemoresistance.

Translational Relevance for Clinical Oncology and Head-Neck Practice

For medical oncologists and otolaryngologists, deciphering these metabolic mechanisms opens valuable therapeutic avenues. Because DFMO is an established agent with a well-characterized safety profile, repurposing it as an adjunct alongside standard platinum-based chemotherapy warrants accelerated clinical investigation. Biomarker-driven stratification based on plasma EBV DNA titers and tumor ODC1 expression could help identify high-risk patients who would benefit most from polyamine-targeted combination regimens.

Furthermore, restoring innate immune sensing through metabolic blockade suggests compelling synergy with immune checkpoint inhibitors. As modern oncology moves toward multimodal approaches, targeting the intersection of viral oncogenesis, polyamine metabolism, and innate immunity provides a strong scientific rationale to design future clinical trials aimed at improving cure rates in locally advanced and recurrent nasopharyngeal carcinoma.

Frequently Asked Questions

How does EBV induce ODC1 upregulation in nasopharyngeal carcinoma?

The Epstein-Barr virus lytic transactivator protein BZLF1 directly binds to the promoter region of the host ODC1 gene. This direct interaction initiates robust transcriptional upregulation of ODC1, thereby accelerating the rate-limiting step of polyamine biosynthesis in infected nasopharyngeal epithelial cancer cells.

Why does the ODC1-spermidine axis suppress innate antitumor immunity?

Elevated spermidine promotes the conversion of B-DNA to the alternative Z-DNA conformation. This structural shift prevents cytosolic DNA from effectively activating the cGAS-STING signaling pathway, blunting type I interferon production and shielding cisplatin-damaged cancer cells from innate immune surveillance.

What is the clinical role of DFMO in overcoming chemoresistance?

Difluoromethylornithine (DFMO) irreversibly inhibits ODC1, depleting intracellular polyamines. This depletion prevents Z-DNA formation, restores cGAS-STING innate immune activation, and synergistically resensitizes EBV-positive nasopharyngeal carcinoma cells to cisplatin-induced apoptosis in experimental preclinical models.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized medical guidance. Refer to the latest local and national guidelines for clinical practice.

References

Li Y et al. EBV-Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma. Adv Sci (Weinh). 2026 Aug 15. doi: 10.1002/advs.77204. PMID: 42603298.

Kaneda A, Fullwood MJ et al. Epstein-Barr virus hijacks host genome boosting nasopharyngeal carcinoma progression. EBioMedicine. 2024;102:105045. doi: 10.1016/j.ebiom.2024.105045.

Liu SL, Sun XS, Liu LT et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy. Aging (Albany NY). 2020;12(6):4931-4940. doi: 10.18632/aging.102920.